Login to Your Account

Adocia Shares Plunge as Lilly Terminates Diabetes Alliance

By Cormac Sheridan
Staff Writer

Wednesday, July 31, 2013
Shares in Adocia SAS plunged by as much as 45 percent Tuesday on news that Eli Lilly and Co. has pulled out of an alliance to develop an ultra-fast-acting insulin analogue for diabetes based on Adocia's Biochaperone formulation technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription